Protai's AI Platform to Showcase New Cancer Drug Breakthroughs

TEL AVIV, Israel – February 10, 2026 – AI drug discovery startup Protai is preparing for a pivotal spring, announcing a tour of five major international scientific conferences where it will unveil significant advancements from its novel discovery engine. The presentations are set to provide the first detailed look at the preclinical performance of its lead cancer-fighting agent, PRT-001, and offer validation for its underlying AIMS™ artificial intelligence platform.

Beginning in March, the company's leadership, including CEO Eran Seger and CTO Kirill Pevzner, will present at a series of high-profile events spanning from the HDX-MS conference in Strasbourg to the prestigious American Association for Cancer Research (AACR) annual meeting in San Diego. The announcements signal Protai's transition from a promising startup to a potential contender in the highly competitive field of oncology drug development, ready to put its technology to the test on the global stage.

Beyond the Genome: The Proteomics-Aware Advantage

At the heart of Protai's strategy is its AIMS™ platform, an engine designed to look beyond genetic code and into the dynamic, complex world of proteins—the functional machinery of the cell. While many AI drug discovery platforms focus on genomics or static protein structures, Protai's approach integrates mass-spectrometry-based structural proteomics with advanced AI modeling. This allows it to map how proteins interact, change shape, and function within their natural environment inside a diseased cell.

This “proteomics-aware” methodology is crucial because genetic biomarkers, while useful, are only applicable in a fraction of cancers, estimated to be around 15% of tumors. By measuring proteins directly, Protai aims to identify disease drivers and patient populations that are invisible to genomics-based methods. The company has built an extensive data acquisition capability, leveraging over 100,000 banked tumor samples through collaborations with leading hospitals to create comprehensive maps of protein activity in various cancers.

“By combining proteomics-driven experimental evidence with next-generation AI modeling, we are revealing opportunities that were previously invisible to classical drug discovery methods,” said Eran Seger, Protai's CEO, in a recent statement. He emphasized that the upcoming presentations will showcase how this synergy can “rapidly generate highly effective drugs for huge clinical unmet needs.”

This focus on functional proteomics places Protai at the cutting edge of a major trend in biotech. As the limitations of purely genomic approaches become clearer, the industry is increasingly turning to AI to make sense of the immense complexity of the proteome, seeking a more complete picture of disease biology to guide the development of more effective medicines.

A Precision Strike on a Key Cancer Driver

The first major test of the AIMS™ platform's power is PRT-001, a drug candidate described by the company as a “best-in-class” degrader targeting KAT6A. The protein KAT6A, a lysine acetyltransferase, has emerged as a significant therapeutic target, particularly in estrogen receptor-positive (ER+) breast cancer, where it is amplified in up to 15% of patients. KAT6A plays a critical role in regulating genes that drive cancer cell growth and survival.

Protai is entering a competitive but promising field. Pfizer is already in clinical trials with a KAT6A/B inhibitor, PF-07248144, which has shown durable antitumor activity in patients with advanced breast cancer. Meanwhile, Prelude Therapeutics is also developing what it calls the “industry's first” oral selective KAT6A degrader, with plans to file for clinical trials in mid-2026.

Protai's PRT-001 is also a degrader, a newer class of medicine that, unlike traditional inhibitors that merely block a protein's function, works by flagging the target protein for complete destruction by the cell's own disposal machinery. This approach can offer deeper and more sustained therapeutic effects and has the potential to work at lower doses, possibly improving safety and tolerability.

The scientific community will be watching closely as Protai presents its “new in vivo results” for PRT-001. The data, expected to be detailed in abstracts and presentations for conferences like the TPD Summit Europe and AACR 2026, will be crucial for substantiating the “best-in-class” claim. Researchers and clinicians will be looking for evidence of superior efficacy, selectivity, and a favorable safety profile compared to both existing inhibitors and competing degraders in development.

From Stealth to Spotlight: Building a Biotech Contender

The ambitious conference schedule marks a clear strategic step for Protai to assert its position in the biotech landscape. After emerging from stealth in 2022, the company has methodically built its scientific and financial foundation, securing a total of $20 million in seed funding. The financing was led by Grove Ventures and Pitango Healthtech, with Copenhagen-based Maj Invest Equity Fund joining in a later extension.

This capital is being deployed to advance Protai’s internal oncology pipeline, led by PRT-001, and to expand its discovery activities. The company has established its own R&D laboratories in Israel and has assembled a formidable team of advisors to guide its strategy. The advisory board includes world-renowned oncology experts from institutions like MD Anderson Cancer Center, and its board of directors includes seasoned biotech entrepreneurs like Dr. Sharon Shacham, founder of Karyopharm Therapeutics.

This combination of proprietary technology, a promising lead asset, strong financial backing, and deep scientific expertise positions Protai as a company to watch. The upcoming presentations are more than just a scientific update; they are a calculated move to attract potential pharmaceutical partners, investors, and top talent by demonstrating tangible results from its AI-driven platform.

As the industry continues to grapple with the high costs and low success rates of traditional drug development, the convergence of AI and novel therapeutic modalities like protein degradation represents a powerful new paradigm. Protai has made bold claims about its ability to navigate this new landscape. For the company, the coming months are not just about presenting data; they are about proving that its vision for a proteomics-driven, AI-powered future of medicine is finally within reach.